MedPath

Found 549959 clinical trials

Sort by:

IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

Not Applicable

Not yet recruiting

Conditions: Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Cisplatin
Drug: IBI363
Drug: Carboplatin
Drug: Keytruda

First Posted Date: 2025-08-14

Last Posted Date: 2025-08-14

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 170

Registration Number: NCT07122687

Locations: 🇨🇳
Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China

Anal Cancer Prevention in High-Risk Categories of Men Who Have Sex With Men

Not Applicable

Not yet recruiting

Conditions: Anal HSIL
Anal AIN3
Anal HPV Infection

First Posted Date: 2025-08-14

Last Posted Date: 2025-08-14

Lead Sponsor: Bispebjerg Hospital

Target Recruit Count: 700

Registration Number: NCT07123558

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

Recruiting

Conditions: Rheumatoid Arthritis (RA)
Hidradenitis Suppurativa (HS)

First Posted Date: 2025-08-14

Last Posted Date: 2025-08-14

Lead Sponsor: Sonoma Biotherapeutics, Inc.

Target Recruit Count: 36

Registration Number: NCT07123038

Locations: 🇺🇸
UCSF Medical Center, San Francisco, California, United States
🇺🇸
Stanford Medical Center, Stanford, California, United States
🇺🇸
University of Colorado, Aurora, Colorado, United States

and more 7 locations

Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors

Not Applicable

Active, not recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: SYS6045

First Posted Date: 2025-08-14

Last Posted Date: 2025-08-14

Lead Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.

Target Recruit Count: 266

Registration Number: NCT07122063

Locations: 🇨🇳
The First Hospital of China Medical University, Shenyang, Liaoing, China

Effectiveness of Dry Eye Treatment With Diquafosol Sodium 3% After Phaco Surgery

Completed

Conditions: Dry Eye Disease

Interventions: Drug: Diquafosol Sodium 3%

First Posted Date: 2025-08-14

Last Posted Date: 2025-08-14

Lead Sponsor: Le Xuan Cung

Target Recruit Count: 60

Registration Number: NCT07122635

Locations: 🇻🇳
Vietnam National Eye Hospital, Hanoi, Vietnam

Neurofeedback to Reduce Spontaneous Recovery of Threat Expectancy

Not Applicable

Recruiting

Conditions: Healthy

First Posted Date: 2025-08-14

Last Posted Date: 2025-08-14

Lead Sponsor: Trustees of Princeton University

Target Recruit Count: 40

Registration Number: NCT07122739

Locations: 🇺🇸
Princeton Neuroscience Institute, Princeton, New Jersey, United States

Effect of Bitopertin on the Liver and on Levels of Protoporphyrin IX in Bile, Blood, Liver, and Stool in Patients With Erythropoietic Protoporphyria/X-linked Protoporphyria and Increased Liver Stiffness and/or Liver Enzymes at Baseline

Not Applicable

Not yet recruiting

Conditions: Protoporphyria

Interventions: Drug: bitopertin

First Posted Date: 2025-08-14

Last Posted Date: 2025-08-14

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 10

Registration Number: NCT07123363

A Study to Learn About a Vaccine Against E Coli in Healthy Adults

Not Applicable

Not yet recruiting

Conditions: Healthy Participants

Interventions: Drug: E coli vaccine 1 Dose A
Drug: E coli vaccine 1 Dose B
Drug: E coli vaccine 2
Drug: E coli vaccine 3
Drug: E coli Vaccine 4 Dose A
Drug: E coli Vaccine 4 Dose B
Drug: E coli Vaccine 4 Dose C
Drug: E coli Vaccine 5 Dose A
Drug: E coli Vaccine 5 Dose B
Drug: Placebo

First Posted Date: 2025-08-14

Last Posted Date: 2025-08-14

Lead Sponsor: Pfizer

Target Recruit Count: 310

Registration Number: NCT07122986

Locations: 🇺🇸
Diablo Clinical Research, Inc., Walnut Creek, California, United States
🇺🇸
CTI Clinical Research Center, Cincinnati, Ohio, United States

Clinical Investigation for the PoliaValve Aortic Heart Valve- India

Not Applicable

Not yet recruiting

Conditions: AORTIC VALVE DISEASES
Aortic Valve Stenosis
Aortic Valve Regurgitation

First Posted Date: 2025-08-14

Last Posted Date: 2025-08-14

Lead Sponsor: Suzhou Hearthill Medical Technology Co.,LTD

Target Recruit Count: 50

Registration Number: NCT07123766

Outcome of Partial Pulpotomy in Moderate and Severe Pulpitis

Not Applicable

Recruiting

Conditions: Extremely Deep Caries
Moderate Pulpitis
Severe Pulpitis

First Posted Date: 2025-08-14

Last Posted Date: 2025-08-14

Lead Sponsor: Postgraduate Institute of Dental Sciences Rohtak

Target Recruit Count: 120

Registration Number: NCT07123025

Locations: 🇮🇳
PGIDS Rohtak, Rohtak, Haryana, India

AI-Powered Research

Premium Access

IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

Anal Cancer Prevention in High-Risk Categories of Men Who Have Sex With Men

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors

Effectiveness of Dry Eye Treatment With Diquafosol Sodium 3% After Phaco Surgery

Neurofeedback to Reduce Spontaneous Recovery of Threat Expectancy

Effect of Bitopertin on the Liver and on Levels of Protoporphyrin IX in Bile, Blood, Liver, and Stool in Patients With Erythropoietic Protoporphyria/X-linked Protoporphyria and Increased Liver Stiffness and/or Liver Enzymes at Baseline

A Study to Learn About a Vaccine Against E Coli in Healthy Adults

Clinical Investigation for the PoliaValve Aortic Heart Valve- India

Outcome of Partial Pulpotomy in Moderate and Severe Pulpitis

Product

Company

Legal